Eli Lilly to Pay $3.25B Upfront in $7B Kelonia Gene Therapy Buyout
Eli Lilly will acquire Kelonia Therapeutics for up to $7 billion, including a $3.25 billion upfront payment and $3.75 billion in milestones. The deal secures Kelonia’s lentiviral iGPS in vivo CAR-T platform and clinical asset KLN-1010, expanding Lilly’s oncology pipeline after its Orna Therapeutics acquisition in February.
1. Acquisition Terms
Eli Lilly agreed to acquire Kelonia Therapeutics for up to $7 billion, consisting of a $3.25 billion upfront cash payment and $3.75 billion in clinical, regulatory and commercial milestone payments.
2. Kelonia’s Platform and Pipeline
Kelonia’s lentiviral-based iGPS in vivo gene therapy platform prompts immune cells to produce therapeutic anti-BCMA CAR-T cells, and its pipeline includes Phase I multiple myeloma asset KLN-1010 plus a preclinical bispecific CAR-T targeting BCMA and CD19.
3. Strategic Rationale
Following its February acquisition of Orna Therapeutics, Lilly diversifies its cell and gene therapy technologies, aiming to reduce cost and manufacturing complexity compared with autologous CAR-T approaches.
4. Competitive and Market Implications
By integrating Kelonia’s platform, Lilly positions itself in the race to commercialize in vivo CAR-T therapies despite safety questions around high-dose lentiviral delivery, potentially accelerating global access to these treatments.